

Friday Satellite Symposia

Preceding the 64th ASH Annual Meeting and Exposition

STATE-OF-THE-ART CMV CARE:

Experts' Perspectives on Primary/Secondary
Prevention and Management of
Refractory/Resistant Infections

IN-PERSON + LIVE STREAMING SATELLITE SYMPOSIUM

FRIDAY, DECEMBER 9, 2022

11:00 AM – 1:00 PM CST

PROGRAM CHAIR

Genovefa A. Papanicolaou, MD

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.

Dear Colleague:

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend State-of-the-Art CMV Care: Experts' Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections.

Current management strategies for prevention of CMV infections in transplant patients who are seropositive or have seropositive donors include antiviral prophylaxis and preemptive therapy. There is an urgent need for novel therapies that can be used for treatment of resistant infections that have fewer toxicities, greater potency, and lack of cross-resistance with current therapies. This satellite symposium highlights current and emerging therapeutic options for patients who experience CMV infections post HSCT, and features expert faculty who will review evolving concepts in the prevention and management of CMV infections in transplant recipients.

In working together with PER®, we strive to make this activity, along with all PER® accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients who have received hematopoietic stem cell transplants.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of CMV infections. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Genovefa A. Papanicolaou, MD

Professor of Medicine, Weill Cornell Medical College
Attending Physician, Infectious Disease Service
Memorial Sloan Kettering Cancer Center
New York, NY

Jim Palatine

President
Physicians' Education Resource®, LLC
Cranbury, NJ
jpalatine@mjh Lifesciences.com

AGENDA

10:15 AM	Registration and Brunch	
11:00 AM	Welcome and Introductions	Genovefa A. Papanicolaou, MD
11:05 AM	Risk Factors and Impact on Treatment Outcomes of CMV for Patients Post-HSCT	Guenther Koehne, MD, PhD
11:20 AM	Medical Crossfire®: How We Assess CMV Risk and Monitor Patients for CMV	Moderator: Genovefa A. Papanicolaou, MD
11:35 AM	Current and Emerging Primary as well as Secondary Prevention Strategies for CMV	Sanjeet Singh Dadwal, MD
11:55 AM	Medical Crossfire®: Preventing CMV Infections in our Patients who Undergo HSCT	Moderator: Genovefa A. Papanicolaou, MD
12:15 PM	Resistant/Refractory CMV Infections: Current and Emerging Approaches	Roy F. Chemaly, MD, MPH, FIDSA, FACP
12:35 PM	Medical Crossfire®: Treating CMV Infections in our Patients who Undergo HSCT	Moderator: Genovefa A. Papanicolaou, MD
12:50 PM	Program Summary and Adjourn	Genovefa A. Papanicolaou, MD

Upcoming PER® Conferences

2022

Inaugural International Congress Pediatric Oncology

December 16

2023

The 1st Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™

Honolulu, HI

January 21

20th Annual Winter Lung Conference®

Hollywood, FL

February 3-5

19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Dallas, TX

February 4

27th Annual International Congress on Hematologic Malignancies®

Miami Beach, FL

February 23-26

40th Annual Miami Breast Cancer Conference®

Miami Beach, FL

March 2-5

NYGU™ 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

New York, NY

March 10-11

8th Annual School of Gastrointestinal Oncology®

Orlando, FL

May 6

7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards

May 6

14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

May 13

22nd Annual International Congress on the Future of Breast Cancer® East

New York, NY

July 15-16

24th Annual International Lung Cancer Congress®

Huntington Beach, CA

July 27-29

22nd Annual International Congress on the Future of Breast Cancer® West

San Diego, CA

July 28-29

20th Annual Meeting of the International Society of Gastrointestinal Oncology®

Tempe, AZ

October 13-14

21st Annual School of Breast Oncology®

Atlanta, GA

November 2-4

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®

New York, NY

November 8-10

18th Annual New York Lung Cancers Symposium®

New York, NY

November 11



Virtual Conference



In-Person + Virtual Conference



In-Person Conference

Target Audience

This educational program is directed toward hematologists, medical oncologists, specialty pharmacists, researchers, and investigators who treat or are interested in the prevention and treatment of transplant-related CMV infection. Other allied health care professionals involved in prevention and management of transplant-related CMV infection will also be invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Describe risk factors for CMV and assess the impact of CMV on treatment outcomes for patients who undergo HSCT
- Outline current and emerging strategies for primary and secondary prevention of CMV infection in patients undergoing HSCT
- Detail strategies to integrate evidence-based data and expert recommendations into current clinical practice to prevent and treat CMV infection post-HSCT
- Discuss mechanisms that lead to development of resistant CMV infection as well as current and emerging strategies to address CMV infections resistant or refractory to current antiviral therapies in patients who undergo HSCT

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EDT on Monday, December 12, 2022. To access these materials, please visit <https://www.gotoper.com/cmv1222iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://www.gotoper.com/cmv1222iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until Monday, January 23, 2023.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number UAN: 0661-0000-22-005-L01-P.


Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Merck & Co., Inc. and Takeda Pharmaceuticals, U.S.A., Inc.

Thank you for attending **State-of-the-Art CMV Care: Experts' Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.



Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: Guenther Koehne, MD, PhD and the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Shareholder	Other
Roy Chemaly, MD, MPH, FIDSA, FACP	Merck, Takeda, AiCuris, Ansun, Viracor, Karius, Genentech, Freestyle	ADMA Biologics, Merck, Karius, Ansun, Viracor, Qiagen, Aseptico, Shinoigi, Janssen, Molecular Partners, Oxford Immunotec, AiCuris		Xenex (Stock Options)	
Sanjeet Singh Dadwal, MD	Allovir, Takeda/Shire, Gilead, Ansun Biopharma, Amplyx/Pfizer	Allovir, Merck	Astellas, Merck	Aseptiscope	Advisory board: Aseptiscope, Merck, Cidara
Genovefa Papanicolaou, MD	Merck&Co (MSD)	MSD, Takeda, Behring SLC, Cidara			Allovir (DSMC member), Octapharma (EAC member)

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair

**Genovefa A. Papanicolaou, MD**

Professor of Medicine, Weill Cornell Medical College
Attending Physician, Infectious Disease Service
Memorial Sloan Kettering Cancer Center
New York, NY

Genovefa A. Papanicolaou, MD, is a professor of medicine at Weill Cornell Medical College and an attending physician, Infectious Disease Service, Memorial Sloan Kettering Cancer Center. She specializes in the management of infections in patients with weakened immune systems and monitors all infections at Memorial Sloan Kettering Cancer Center's Bone Marrow Transplant Unit to detect unusual trends and assist in improving outcomes. Her primary research focuses on genetic differences among innate immune responses, which may help explain why some immunocompromised patients are more susceptible to infection than others. The long-term goal of her studies is to identify subsets of immunocompromised patients who are most vulnerable to infection. After obtaining an MD from the National University of Athens School of Medicine, Dr Papanicolaou completed a residency at Tufts New England Medical Center.

Faculty

**Roy F. Chemaly, MD, MPH, FIDSA, FACP**

Professor of Medicine
Chief Infection Control Officer
Director, Clinical Virology Research
MD Anderson Cancer Center
Houston, TX

Roy F. Chemaly, MD, MPH, FIDSA, FACP, is a professor of medicine and chief infection control officer at the University of Texas MD Anderson Cancer Center. Dr Chemaly's interests include studies on the epidemiology, severity, prognosis, prevention and treatment of respiratory viral infections in immunocompromised cancer patients as well as the prevention of health care-associated infections. Dr Chemaly conducts clinical trials for the management and prevention of viral infections in cancer patients, hematopoietic cell transplant (HCT) recipients, as well as on the composition of the upper respiratory tract microbiome as a risk factor for lower respiratory tract infections. He is also conducting clinical trials using CMV-specific immunoassays to predict CMV reactivation or progression. In addition, Dr Chemaly and his lab team are conducting studies on whole genome sequencing for VRE, phages, and CMV to establish the transmission networks and the resistance and virulence genes associated with worse outcomes.

Faculty

**Sanjeet Singh Dadwal, MD**

Chief, Division of Infectious Diseases
City of Hope
Durate, CA

Sanjeet Singh Dadwal, MD, is chief of the Division of Infectious Diseases at City of Hope. He specializes in treating patients with cancer who develop infections. His research focuses on understanding the mechanics of such infections and finding new ways to control them. After receiving a medical degree in New Delhi, India, he completed a residency at SUNY Downstate Health Sciences University and a fellowship at Charles R. Drew University of Medicine and Science/MLK Community Healthcare in Los Angeles. Dr Dadwal has published dozens of peer-reviewed articles and oversees a long list of clinical trials.

**Guenther Koehne MD, PhD**

Deputy Director, Chief of Blood & Marrow Transplant and Hematologic Oncology
Miami Cancer Institute
Miami, FL


Guenther Koehne, MD, PhD, is an internationally renowned expert in the application of both autologous and allogeneic stem cell transplantation for the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases. Dr Koehne serves as deputy director and chief of blood and marrow transplant and hematologic oncology at Miami Cancer Institute, part of Baptist Health South Florida. Prior to joining the Institute in 2017, he was a leading physician in adult bone marrow transplantation at Memorial Sloan Kettering Cancer Center in New York and an associate professor of medicine at Weill Cornell Medical College. Dr Koehne is recognized for his work in adoptive immunotherapeutic approaches with antigen-specific, donor-derived T lymphocytes to treat viral complications following allogeneic transplants; and for the development of novel treatments for high-risk multiple myeloma, minimal residual disease of leukemia and relapsed disease post-allogeneic stem cell transplantation.

Did you miss one of our sessions?


Check out the On-Demand Video Updates
from the Annual Hematology Meeting

—*Rapid Archive from* → **NEW ORLEANS**


Archive will be available 24 hours after the live program ends.



**Optimized use of MRD in
Hematologic Malignancies**




State-of-the-Art CMV Care




**Emerging Treatments for
Anemia in CKD**



**Holistic Approaches in
Sickle Cell Disease Treatment**




**Diagnosis and Treatment of
Hemolytic Anemias**




**Optimized Treatments for
ALL in Adolescents and Adults**




**Multidisciplinary Management
of BPDCN**




**Maximizing Clinical Practice
for Hodgkin Lymphoma**



**State-of-the-Art Care for
MF and PV**




**Exploring Gene Therapy in
Hemophilia B**



**Diagnosing Uncommon
Hematologic Disorders**



**Novel Therapies to Prevent
and Treat GvHD**



**Novel Treatments for Indolent
and Aggressive B-Cell Lymphomas**



**Treating Transfusion-Related
Iron Overload**



Scan the QR code below
or visit gotoper.com/ASH22
to view the symposia archive.

 **PER**[®]
Physicians'
Education
Resource, LLC
gotoper.com